Loading market dashboard
HealthEquity, Inc.
HQYHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.
The consensus price target hints at a 33.5% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.
HealthEquity, Inc. (HQY) Q1 2027 Earnings Call Transcript
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
On May 28, 2026, HealthEquity Inc (HQY) shares rose by 4.6%, bringing the current price to $90.52. Over the past year, the stock has seen a 52-week range from a
HealthEquity (HQY) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.97 per share a year ago.
HealthEquity NASDAQ: HQY raised its fiscal 2027 outlook after reporting higher first-quarter profitability, record revenue in key categories and expanded margins, with management pointing to account growth, deeper member engagement and operating efficiencies from technology and artificial intelligence.
Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year. Adjusted EBITDA increased 17% to $164.5 million, and Adjusted EBITDA margin increased to 46% from 42% last year.
Picture a dual-income couple with combined wages well into the high six figures. They already max the 401(k). Their employer offers a high-deductible health plan, and they keep choosing the lower-premium PPO out of habit. That habit is costing them the most tax-advantaged account in the entire IRS code. The HSA is the only vehicle... The Triple Tax Free HSA Account High Earners Are Funding Before Maxing Their 401(k)
HealthEquity is a leading HSA administrator, benefiting from rising healthcare costs and recent legislative tailwinds expanding its addressable market. Revenue grew 9% in FY2026 to $1.313 billion, with significant margin expansion and a standout 17% growth in custodial revenue driven by enhanced rate migration. Management projects further yield increases in FY2027, and a major low-yield contract expiry is set to boost custodial revenue meaningfully.
HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for HealthEquity (HQY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2026.
Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DRAPER, Utah, May 05, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced plans to release financial results for its first quarter of fiscal 2027, after the close of regular stock market trading on Thursday, May 28, 2026. Following the news release, HealthEquity management will host a conference call for investors on Thursday, May 28, 2026, at 4:30 p.m.
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HealthEquity (NASDAQ: HQY - Get Free Report) and bioMerieux (OTCMKTS:BMXMF - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Institutional and Insider Ownership 99.6% of HealthEquity shares are held
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HealthEquity is upgraded from 'Hold' to 'Buy,' reflecting visible operating leverage and durable growth drivers. HQY's fiscal Q4 2026 saw 7% revenue growth, 500+ bps margin expansion, and 23% adjusted EBITDA growth, signaling an earnings inflection. Structural tailwinds include expanded HSA eligibility, rising engagement, and a shift toward higher-value, compounding accounts.
Investors looking for stocks in the Medical Services sector might want to consider either Solventum (SOLV) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
XWELL (NASDAQ: XWEL - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Analyst Recommendations This is a summary of current ratings and
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Capricorn Fund Managers Ltd purchased a new position in HealthEquity, Inc. (NASDAQ: HQY) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 75,602 shares of the company's stock, valued at approximately $6,926,000. HealthEquity accounts for 1.7% of Capricorn Fund Managers Ltd's
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.
Econ Financial Services Corp grew its holdings in shares of HealthEquity, Inc. (NASDAQ: HQY) by 39.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,249 shares of the company's stock after buying an additional 7,770 shares during the period. Econ Financial
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Shares of HealthEquity, Inc. (NASDAQ: HQY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has
DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the “Board”) effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent.
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks presents investors with the better value opportunity right now?
Establishment Labs (NASDAQ: ESTA - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Valuation and Earnings This table compares Establishment Labs and
CIBC Private Wealth Group LLC decreased its position in shares of HealthEquity, Inc. (NASDAQ: HQY) by 81.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 213,406 shares of the company's stock after selling 913,648 shares during the quarter. CIBC Private
Healthequity Inc (NASDAQ: HQY) posted better-than-expected earnings for the fourth quarter on Tuesday.
HealthEquity is upgraded to a buy, with ~25% upside potential over the next year as custodial revenue normalizes and legislative tailwinds strengthen. Shares trade at ~17x forward earnings, with EPS expected to grow 15% in FY27 and at least 10% in calendar 2027, driven by repricing of cash yields. Secular HSA account growth, an improved legislative environment, and rising custodial yields underpin HQY's earnings visibility and margin expansion.
HealthEquity, Inc. (HQY) Q4 2026 Earnings Call Transcript
The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended January 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HealthEquity (HQY) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.69 per share a year ago.
Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion. Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.
HealthEquity, Inc. (NASDAQ: HQY) will release earnings results for its fourth quarter, after the closing bell on Tuesday, March 17.
Boone Capital Management purchased 212,856 shares of HealthEquity; trade value of $19.5 million as reported in the SEC filing. The position represents 6.12% of 13F reportable assets under management.
ArrowMark Colorado Holdings LLC cut its stake in shares of HealthEquity, Inc. (NASDAQ: HQY) by 39.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 231,902 shares of the company's stock after selling 150,804 shares during the period. ArrowMark Colorado
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for HealthEquity (HQY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended January 2026.
HealthEquity (NASDAQ: HQY - Get Free Report) is expected to release its Q4 2026 results after the market closes on Tuesday, March 17th. Analysts expect HealthEquity to post earnings of $0.89 per share and revenue of $332.4790 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2026 earning overview page for the
